Key result
Cardioprotective therapy restores myocardial function in severe anti-HER2-associated LV systolic dysfunction.
Why the study?
Anti-HER2 therapy is standard of care for HER2-positive breast cancer, but it can cause left ventricular systolic dysfunction of varying severity, presenting challenges in balancing oncological efficacy and cardiovascular safety.
Case Report (n=1)
Illustrates that severe left ventricular systolic dysfunction induced by trastuzumab and pertuzumab after anthracycline exposure can recover with cardioprotective therapy, highlighting the need to balance oncological efficacy and cardiovascular safety.
Answers are grounded in this paper and cite their sources.
May support reversibility of anti-HER2 cardiotoxicity with cardioprotection; hypothesis-generating and should not yet change practice.
Therapy aimed at suppressing HER2 (human epidermal growth factor receptor 2) gene or anti-HER2 therapy (trastuzumab, pertuzumab) is the standard of care for HER2-positive breast cancer; however, it can cause cardiotoxicity in the form of systolic dysfunction of the left ventricle of varying severity. This article presents a case of a 52-year-old female patient with metastatic HER2-positive breast cancer who developed severe left ventricular systolic dysfunction with a significant reduction in left ventricular ejection fraction during combination therapy with trastuzumab and pertuzumab, following prior treatment with doxorubicin (an anthracycline) and paclitaxel. The diagnostic workup and patient management strategy are described in detail, with noted recovery of myocardial function following cardioprotective therapy. Particular attention is paid to the challenges of balancing oncological efficacy and cardiovascular safety when deciding on the continuation of anti-HER2 therapy.
No takes yet. Share an insight, caveat, or question.
Козявин et al. (2026) conducted a case report in Severe left ventricular systolic dysfunction associated with anti-HER2 therapy in metastatic HER2-positive breast cancer (n=1). Cardioprotective therapy was evaluated on Left ventricular systolic function recovery. Cardioprotective therapy resulted in recovery of myocardial function in a 52-year-old woman with severe anti-HER2 therapy-associated left ventricular systolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: